Christian T. Ruff

Christian T. Ruff

Auto-generated profile, based on publicly available information

Christian T. Ruff

TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in The Lancet
Verified
Journal Article
Closed access
CRChristian T Ruff
Christian T Ruff
RGRobert P Giugliano
Robert P Giugliano
EBEugene Braunwald
Eugene Braunwald
EHElaine B Hoffman
Elaine B Hoffman
NDNaveen Deenadayalu
Naveen Deenadayalu
EAElliott M Antman
Elliott M Antman

5 January 2022 in Circulation
Verified
Journal Article
Closed access
PDF file
ACAnthony P. Carnicelli
Anthony P. Carnicelli
HHHwanhee Hong
Hwanhee Hong
SCStuart J. Connolly
Stuart J. Connolly
JEJohn Eikelboom
John Eikelboom
RGRobert P. Giugliano
Robert P. Giugliano
OIon behalf of the COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) Investigators
on behalf of the COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) Investigators
Background: Direct oral anticoagulants (DOACs) are preferred over warfarin for stroke prevention in atrial fibrillation. Meta-analyses using individual patient data offer substantial advantages over study-level data. Methods: We used individual patient data from the COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) database, which includes all patients randomized in the 4 pivotal trials of DOACs versus warfarin in atrial fibrillation (RE-LY [Randomized Evaluation of Long-Term Anticoagulation Therapy], ROCKET AF [Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation], ARISTOTLE [Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation], and ENGAGE AF-TIMI 48 [Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48]), to perform network meta-analyses using a stratified Cox model with random effects comparing standard-dose DOAC, lower-dose DOAC, and warfarin. Hazard ratios (HRs [95% CIs]) were calculated for efficacy and safety outcomes. Covariate-by-treatment interaction was estimated for categorical covariates and for age as a continuous covariate, stratified by sex. Results: A total of 71 683 patients were included (29 362 on standard-dose DOAC, 13 049 on lower-dose DOAC, and 29 272 on warfarin). Compared with warfarin, standard-dose DOACs were associated with a significantly lower hazard of stroke or systemic embolism (883/29 312 [3.01%] versus 1080/29 229 [3.69%]; HR, 0.81 [95% CI, 0.74–0.89]), death (2276/29 312 [7.76%] versus 2460/29 229 [8.42%]; HR, 0.92 [95% CI, 0.87–0.97]), and intracranial bleeding (184/29 270 [0.63%] versus 409/29 187 [1.40%]; HR, 0.45 [95% CI, 0.37–0.56]), but no statistically different hazard of major bleeding (1479/29 270 [5.05%] versus 1733/29 187 [5.94%]; HR, 0.86 [95% CI, 0.74–1.01]), whereas lower-dose DOACs were associated with no statistically different hazard of stroke or systemic embolism (531/13 049 [3.96%] versus 1080/29 229 [3.69%]; HR, 1.06 [95% CI, 0.95–1.19]) but a lower hazard of intracranial bleeding (55/12 985 [0.42%] versus 409/29 187 [1.40%]; HR, 0.28 [95% CI, 0.21–0.37]), death (1082/13 049 [8.29%] versus 2460/29 229 [8.42%]; HR, 0.90 [95% CI, 0.83–0.97]), and major bleeding (564/12 985 [4.34%] versus 1733/29 187 [5.94%]; HR, 0.63 [95% CI, 0.45–0.88]). Treatment effects for standard- and lower-dose DOACs versus warfarin were consistent across age and sex for stroke or systemic embolism and death, whereas standard-dose DOACs were favored in patients with no history of vitamin K antagonist use ( P =0.01) and lower creatinine clearance ( P =0.09). For major bleeding, standard-dose DOACs were favored in patients with lower body weight ( P =0.02). In the continuous covariate analysis, younger patients derived greater benefits from standard-dose (interaction P =0.02) and lower-dose DOACs (interaction P =0.01) versus warfarin. Conclusions: Compared with warfarin, DOACs have more favorable efficacy and safety profiles among patients with atrial fibrillation.

1 October 2010 in American Heart Journal
Verified
Journal Article
Closed access
CRChristian T. Ruff
Christian T. Ruff
RGRobert P. Giugliano
Robert P. Giugliano
EAElliott M. Antman
Elliott M. Antman
SCSharon E. Crugnale
Sharon E. Crugnale
TBTomas Bocanegra
Tomas Bocanegra
EBEugene Braunwald
Eugene Braunwald

1 June 2015 in The Lancet
Verified
Journal Article
Closed access
CRChristian T Ruff
Christian T Ruff
RGRobert P Giugliano
Robert P Giugliano
EBEugene Braunwald
Eugene Braunwald
DMDavid A Morrow
David A Morrow
SMSabina A Murphy
Sabina A Murphy
EAElliott M Antman
Elliott M Antman

25 February 2020 in Circulation
Verified
Journal Article
Closed access
PDF file
NMNicholas A. Marston
Nicholas A. Marston
FKFrederick K. Kamanu
Frederick K. Kamanu
FNFrancesco Nordio
Francesco Nordio
YGYared Gurmu
Yared Gurmu
CRCarolina Roselli
Carolina Roselli
CRChristian T. Ruff
Christian T. Ruff
Background: The ability of a genetic risk score to predict risk in established cardiovascular disease and identify individuals who derive greater benefit from PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition has not been established. Methods: We studied 14 298 patients with atherosclerotic cardiovascular disease from the FOURIER trial (Further Cardiovascular Outcomes Researh With PCSK9 Inhibition in Subjects With Elevated Risk). A 27–single-nucleotide polymorphism genetic risk score defined low (quintile 1), intermediate (quintiles 2–4), and high (quintile 5) genetic risk. Patients were also categorized by major atherosclerotic risk factors including diabetes mellitus, hypertension, low-density lipoprotein cholesterol ≥100 mg/dl, and smoking; multiple (≥2) risk factors was considered high clinical risk. Outcomes consisted of major coronary events (coronary heart death, myocardial infarction, or coronary revascularization) and major vascular events (major coronary events and ischemic stroke). Median follow-up was 2.3 years. Results: After we adjusted for clinical factors, the genetic risk score was associated with risk for both major vascular events ( P trend =0.007) and major coronary events ( P trend <0.0001). Individuals with intermediate and high genetic risk scores had 1.32- and 1.66-fold increased hazard for major coronary events, respectively. Elevated genetic risk was additive to major atherosclerotic risk factors and identified patients more likely to benefit from evolocumab. There was no benefit for major vascular events in patients without multiple clinical risk factors or high genetic risk (hazard ratio [HR], 0.99; absolute risk reduction [ARR], 0.06%, P =0.89). In contrast, there was a 15% relative risk reduction (HR, 0.85 [0.74–0.98], P =0.024) and a 1.6% ARR in patients with multiple clinical risk factors but without high genetic risk and a 25% relative risk reduction (HR, 0.75 [0.60–0.94], P =0.013), and 3.0% ARR in patients with high genetic risk, irrespective of clinical risk ( P trend for HR=0.095, ARR P trend =0.034). Patients with high genetic risk who received evolocumab had event rates similar to patients with a low burden of both genetic and clinical risk. Conclusion: Patients without multiple clinical risk factors or high genetic risk had a low event rate and did not appear to derive benefit from evolocumab over 2.3 years. Conversely, patients with multiple clinical risk factors but without high genetic risk had intermediate risk and intermediate risk reduction. Patients with high genetic risk, regardless of clinical risk, had a high event rate and derived the greatest benefit from evolocumab, which mitigated this risk.

1 September 2016 in JACC
Verified
Journal Article
Closed access
JSJan Steffel
Jan Steffel
RGRobert P. Giugliano
Robert P. Giugliano
EBEugene Braunwald
Eugene Braunwald
SMSabina A. Murphy
Sabina A. Murphy
MMMichele Mercuri
Michele Mercuri
CRChristian T. Ruff
Christian T. Ruff